DBV Technologies (NASDAQ:DBVT) Shares Gap Up – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $14.14, but opened at $14.88. DBV Technologies shares last traded at $14.9430, with a volume of 20,999 shares traded.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DBVT. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citizens Jmp raised their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Weiss Ratings cut DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Finally, Guggenheim reiterated a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DBV Technologies has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Stock Down 3.0%

The stock has a market cap of $913.02 million, a PE ratio of -4.14 and a beta of -0.93. The stock’s fifty day moving average price is $14.87 and its 200 day moving average price is $18.24.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, equities research analysts expect that DBV Technologies S.A. will post -2.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Elmind Capital LP bought a new position in DBV Technologies during the 1st quarter valued at about $5,536,000. Perceptive Advisors LLC bought a new stake in shares of DBV Technologies in the first quarter worth approximately $20,146,000. Diversify Wealth Management LLC purchased a new position in shares of DBV Technologies during the first quarter valued at approximately $1,293,000. Dorsey Wright & Associates purchased a new position in shares of DBV Technologies during the first quarter valued at approximately $2,142,000. Finally, UBS Group AG lifted its position in DBV Technologies by 165,347.3% during the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after purchasing an additional 244,714 shares during the period. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.